Abstract 1169P
Background
Acral lentiginous melanoma (ALM), although overall a rare type of melanoma, is the most common form of the disease in a number of countries in Latin America, Africa, and Asia; it is associated with a poor prognosis and recurrence. In this study, we seek to gain a better understanding of the tumor-immune components of ALM and their relationship to transcriptional programs.
Methods
Tumour samples were collected from patients undergoing treatment at the National Cancer Institute of Mexico, and have been annotated with vast clinical information. We performed transcriptome sequencing through exome-capture bulk RNA-sequencing on 65 primary tumors from 64 Mexican patients, and did spatial protein profiling using a tissue microarray on 110 tumor segments from 45 patients. Samples were collected at the National Cancer Institute of Mexico and have been annotated with vast clinical information.
Results
We identified differentially expressed genes such as CXCL8, MMP1, and TERT in ulcerated lesions. RNA deconvolution showed a high abundance of cancer-associated fibroblasts (CAFs) and the absence of NK cells. Consensus clustering identified three ALM subgroups based on global gene expression. Integration of spatial protein information confirmed the high abundance of CAFs- associated markers and the absence of CD56. Fibronectin, SMA, and the cancer stem cell marker CD44 were markedly elevated. We investigated expression patterns within particular regions of interest and found that fibronectin, VISTA, SMA, IDO1, CD34, CD45, CD3, HLA-DR, and CD45RO were differentially expressed in non-tumor regions, while tumor ROIs expressed B7-H3, CD127, GAPDH, and Ki-67 significantly at higher levels. Comparisons between RNA and protein for 35 targets are being conducted.
Conclusions
So far, our analyses point to genes that could drive important prognostic characteristics. We confirmed that ALM is characterized by an immunosuppressive tumor microenvironment. The role of CAFs and the mechanisms affecting NK cells require further research. The present project will enhance our understanding of the TME components and the antitumor response in an understudied disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Carla Daniela Robles Espinoza.
Funding
CONACyT A3-S-31603, UNAM PAPIIT IN209422, Welcome Sanger Institute International Fellowship, Melanoma Research Alliance Pilot Award #825924, William Guy Forbeck Research Foundation.
Disclosure
D. Adams: Other, Institutional, Other, DJA is supported by AstraZeneca, OpenTargets and is a paid consultant for Microbiotica: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13